Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2018-07-31 Declaration of Voting R…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated July 31, 2018, titled "Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)" (Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)). It explicitly states that a convertible loan was partially converted into shares, leading to an increase in the total number of shares and votes. This directly relates to a change in the company's capital structure via share issuance resulting from debt conversion. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it describes a specific capital event, nor is it a dividend notice (DIV) or director dealing (DIRS).
2018-07-31 Swedish
Status of the Market Authorisation Application of Apealea in the European Union
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated July 27, 2018, providing an update on the status of a Market Authorisation Application (Apealea) within the European Union regulatory process (CHMP). It announces that the expected oral explanation did not occur and states the company's intention to respond to outstanding issues by a specific date (August 21, 2018). It concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation. Since this is a specific, non-standard regulatory update that doesn't fit into the defined categories like 10-K, ER, or IR, and it is an announcement rather than a full report, the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings). The document length is very short (1773 chars), supporting the idea that it is an announcement/notification rather than a comprehensive report.
2018-07-27 English
Status beträffande Apealeas marknadsansökan hos EMA
Legal Proceedings Report Classification · 99% confidence The document is a press release ("PRESSMEDDELANDE") dated July 27, 2018, concerning an update on a regulatory application status for a drug (Apealea) with the European Medicines Agency (EMA) scientific committee (CHMP). It details procedural steps (written responses required instead of an oral hearing) and provides company background. This type of specific, non-financial, operational/regulatory update that doesn't fit into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, M&A) is best classified as a general regulatory announcement or miscellaneous filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for this type of specific regulatory status update that is not a formal legal proceeding report (LTR) or a standard financial disclosure.
2018-07-27 Swedish
Earnings Release 2018
Earnings Release Classification · 99% confidence The document is titled 'Bokslutskommuniké för räkenskapsåret 1 maj 2017 – 30 april 2018' (Year-end report communication for the fiscal year...). It contains detailed financial summaries for the fourth quarter and the full fiscal year, including net sales, operating result, and net result after tax, comparing them to the previous year. This structure—a summary of full-year and quarterly financial performance, often accompanied by a CEO's comment and operational updates—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since the reporting period covers the full fiscal year (May 1 to April 30), it functions as the primary annual financial disclosure, even if it is not the formal 10-K filing. Given the detailed financial figures and the CEO commentary summarizing the year's performance, it aligns best with the comprehensive nature of an Interim/Quarterly Report (IR), which often includes year-end summaries for non-US companies, or an Earnings Release (ER). Since it covers the full year and provides substantial detail beyond just highlights, IR is a strong candidate, but ER is often used for these communications preceding the 10-K. However, the Swedish term 'Bokslutskommuniké' strongly implies the release of the full annual financial statements summary. In the context of the provided definitions, where '10-K' is the official yearly report and 'IR' is for shorter periods (like half-year), this document, being the comprehensive year-end summary, is closest to a detailed financial report. Since it is a comprehensive report for the full year, and not just a brief announcement, it is classified as an Interim/Quarterly Report (IR) as it serves as the primary periodic financial disclosure for the year, even though it covers 12 months. If it were the formal SEC 10-K, it would be classified as 10-K, but this appears to be the local equivalent summary release. Q4 2018
2018-06-08 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Year-end report' for Oasmia Pharmaceutical AB covering the financial year May 1, 2017 – April 30, 2018. It contains detailed financial statements (consolidated net sales, operating loss, net loss, loss per share), management commentary, business activity updates, and product development status. Since it covers a period shorter than a full fiscal year (the fourth quarter) and provides comprehensive financial data and analysis, it is classified as an Interim/Quarterly Report. Q4 2018
2018-06-08 English
Resultat från Oasmia Pharmaceuticals fas III-studie har presenterats vid ASCOs årliga möte
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that results from a Phase III study for the drug Apealea were presented at the ASCO annual meeting. It details the clinical findings (survival rates, hazard ratios) and provides context about the conference and the drug. This is a direct announcement of scientific/clinical results, not a formal regulatory filing like a 10-K or a comprehensive Interim Report (IR). It is a specific type of announcement detailing clinical trial outcomes, which often falls under general regulatory announcements or investor relations material. Given the options, it is a specific announcement about clinical data presentation. Since there isn't a specific 'Clinical Trial Result Announcement' code, and it is a formal press release detailing scientific progress, it best fits the general 'Regulatory Filings' (RNS) category as a non-standard, material announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a news release. However, the content is highly specific scientific data presentation, which is often disseminated via press release. Since it is not a full report (10-K, IR) or a management discussion (MDA), and it is a formal announcement of scientific progress, RNS is the most appropriate fallback for a material, non-standard announcement, although it shares characteristics with an ER (Earnings Release) in format, but the content is scientific, not financial performance. Given the context of presenting study results, RNS (Regulatory Filings/General Announcement) is the safest classification for this type of material press release.
2018-06-05 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.